Selective delta opioid receptor agonists for inflammatory and neuropathic pain.
In the last decade a number of selective and potent non-peptidic agents became available to explore the usefulness of the delta-opioid receptor in modulation of pain of different origins. As a continuing effort in this field, potent and selective delta-opioid agonists based on the pyrrolomorphinan framework have been designed, synthesised and characterised biologically in our laboratories. In animal models, a selected compound of interest, SB 235863, has proved the concept that selective delta-opioid agonists may have great potential as pain relief agents in inflammatory and neuropathic pain conditions. Importantly, such a compound was free of the unwanted side effects usually associated with narcotic analgesics such as morphine.
Dondio
G
G
SmithKline Beecham SpA, Baranzate di Bollate, Milan, Italy. massimo_dondio@sbphrd.com
Ronzoni
S
S
Farina
C
C
Graziani
D
D
Parini
C
C
Petrillo
P
P
Giardina
G A
GA
D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D015195:Drug Design; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D010146:Pain / Q000188:drug therapy; D017465:Receptors, Opioid, delta / Q000819:agonists*; D013329:Structure-Activity Relationship
D000701:Analgesics, Opioid; D017465:Receptors, Opioid, delta